

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021

<https://marketpublishers.com/r/H3D49CB0761DEN.html>

Date: June 2021

Pages: 61

Price: US\$ 3,500.00 (Single User License)

ID: H3D49CB0761DEN

Abstracts

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021

SUMMARY

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 10 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Chlamydia Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Female Contraception, Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Recurrent Glioblastoma Multiforme (GBM), Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The latest report Human Cytomegalovirus Envelope Glycoprotein B - Drugs In Development, 2021, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration

(RoA) and molecule type. It also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)

The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects

The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development

AlphaVax Inc

Citravi Biosciences LLC

Helocyte Biosciences Inc

Merck & Co Inc

Stadius Biopharma LLC

Trellis Bioscience Inc

VBI Vaccines Inc

Yaso Therapeutics Inc

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles

AVX-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bi-specific Monoclonal Antibody to Target CD3 and Glycoprotein B for Cytomegalovirus (HHV-5) Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cytomegalovirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cytomegalovirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cytomegalovirus vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit gH and gB for Cytomegalovirus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPCM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRL-345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBI-1501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBI-1901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones

Featured News & Press Releases

Jun 08, 2021: VBI Vaccines granted FDA fast track designation for VBI-1901 for the treatment of recurrent GBM

May 20, 2021: VBI Vaccines to present updated phase 2a tumor response and overall survival data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting

Nov 19, 2020: VBI Vaccines announces positive interim Phase 2a data from VBI-1901 in recurrent GBM

Nov 09, 2020: VBI Vaccines announces e-poster presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting

Sep 17, 2020: VBI Vaccines announces biomarker data from VBI-1901 phase 1/2a study in recurrent GBM presented at ESMO Virtual Congress 2020

Sep 14, 2020: VBI Vaccines to present additional biomarker data from VBI-1901 phase 1/2a study in recurrent GBM in an E-Poster at ESMO Virtual Congress 2020

Jun 22, 2020: VBI Vaccines announces data from VBI-1901 presented at AACR 2020: Partial response observed, promising biomarker strategy identified

May 15, 2020: VBI Vaccines announces upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting

Mar 03, 2020: VBI Vaccines doses first recurrent GBM patient in trial of VBI-1901

Mar 03, 2020: VBI Vaccines provides update on part A of ongoing Phase 1/2a study demonstrating overall survival benefit for VBI-1901 vaccine responders in recurrent GBM patients

Nov 22, 2019: VBI Vaccines presents early GBM tumor response and immunologic data from part B of ongoing phase 1/2a study of VBI-1901 at the 2019 SNO Annual Meeting

Nov 11, 2019: VBI Vaccines to present initial phase 1/2a part B data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

Oct 24, 2019: VBI Vaccines to present new immuno-oncology data at the World Vaccine Congress Europe 2019

Sep 11, 2019: VBI to study cancer vaccine with GSK's adjuvant system

Jul 29, 2019: VBI Vaccines announces dosing of first recurrent GBM patient in Part B of ongoing phase 1/2a study of VBI-1901

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by AlphaVax Inc, 2021

Pipeline by Citranvi Biosciences LLC, 2021

Pipeline by Helocyte Biosciences Inc, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Stadius Biopharma LLC, 2021

Pipeline by Trellis Bioscience Inc, 2021

Pipeline by VBI Vaccines Inc, 2021

Pipeline by Yaso Therapeutics Inc, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/H3D49CB0761DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H3D49CB0761DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970